Results 11 to 20 of about 61,872 (307)

Transthyretin, Immature Platelet Fraction, and Mean Platelet Volume in Normotensive and Preeclampsia Pregnancy

Indonesian Biomedical Journal, 2022
BACKGROUND: Transthyretin protein experiences misfolding and aggregation in preeclampsia due to placental ischemia and inflammation. Placental endothelial damage occurring in preeclampsia stimulates the production of larger young platelets in the bone ...
Asri Ragil Kemuning, Herniah Asti Wulanjani, I Edward Kurnia Setiawan Limijadi, Indranila Kustarini Samsuria, Banundari Rachmawati   +4 more
doaj   +1 more source

Utility of Genetic Testing in Patients with Transthyretin Amyloid Cardiomyopathy: A Brief Review

Biomedicines, 2023
Transthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly diagnosed condition. Although wild-type transthyretin amyloidosis (ATTRwt) is the most common ATTR-CM, hereditary transthyretin amyloidosis (ATTRv) may also occur.
Ana-Maria Merino-Merino, Jorge Labrador-Gomez, Ester Sanchez-Corral, Pedro-David Delgado-Lopez, Jose-Angel Perez-Rivera   +4 more
doaj   +1 more source

Amyloidogenicity assessment of transthyretin gene variants

Annals of Clinical and Translational Neurology, 2022
Objective Hereditary transthyretin‐mediated amyloidosis is a treatable condition caused by amyloidogenic variants in the transthyretin‐gene resulting in severe peripheral neuropathy or cardiomyopathy.
Nicolai B. Grether, Felix Napravnik, Thomas Imhof, Reinhold P. Linke, Jan H. Bräsen, Jessica Schmitz, Maike Dohrn, Christian Schneider, Martin K. R. Svačina, Jörg Stetefeld, Manuel Koch, Helmar C. Lehmann   +11 more
doaj   +1 more source

Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid.

New England Journal of Medicine, 2023
BACKGROUND Transthyretin amyloid (ATTR) cardiomyopathy is a progressive and fatal disease caused by misfolded transthyretin. Despite advances in slowing disease progression, there is no available treatment that depletes ATTR from the heart for the ...
P. García-Pavía, Fabian aus dem Siepen, E. Donal, O. Lairez, P. van der Meer, A. Kristen, M. Mercuri, Aubin Michalon, R. Frost, Jan Grimm, R. Nitsch, C. Hock, P. C. Kahr, T. Damy   +13 more
semanticscholar   +1 more source

Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy.

Journal of the American Medical Association (JAMA), 2023
Importance Transthyretin gene silencing is an emerging treatment strategy for hereditary transthyretin (ATTRv) amyloidosis. Objective To evaluate eplontersen, an investigational ligand-conjugated antisense oligonucleotide, in ATTRv polyneuropathy ...
Teresa Coelho, Wilson Marques, N. Dasgupta, C. Chao, Y. Parman, M. França, Yuh-Cherng Guo, J. Wixner, Long-Sun Ro, Cristian R Calandra, P. Kowacs, J. Berk, L. Obici, F. A. Barroso, M. Weiler, I. Conceição, Shiangtung W. Jung, G. Buchele, Michela Brambatti, Jersey Chen, Steven G. Hughes, Eugene Schneider, N. Viney, Ahmad Masri, Morie Gertz, Yukio Ando, J. Gillmore, S. Khella, P. J. B. Dyck, M. Waddington Cruz, Anna Mazzeo, A. Papagianni, Mazen Dimachkie, Ioannis Zaganas, Edward Gane, M. Luigetti, L. Galán Dávila, Michelle Mezei, Juan Gonzalez Moreno, P. Cintas, D. Pareyson, Rebecca Traub, Julie Khoury, C. Estol, Merrilee Needham, David John Adams, M. Polydefkis, T. Brannagan, V. Bril, S. Attarian, Marcelo Rugiero, Barbara Distad, Eleni Zamba Papanicolaou, Kon-Ping Lin, Merrill D. Benson, M. Scheinberg   +55 more
semanticscholar   +1 more source

Health-related quality of life in hereditary transthyretin amyloidosis polyneuropathy: a prospective, observational study [PDF]

, 2020
Background Hereditary Transthyretin Amyloidosis Polyneuropathy is a rare life-threatening neurologic disease that imposes considerable mortality and it is associated with progressive related disabilities.
Coelho, Teresa, Conceição, Isabel, Costa, João, de Carvalho, Mamede, Ferreira, Lara, Inês, Mónica   +5 more
core   +2 more sources

Cardiac Transthyretin Amyloidosis: Hidden in Plain Sight

Case Reports in Medicine, 2021
Amyloidosis is an underappreciated medical condition with symptoms camouflaging as common medical comorbidities leading to its underdiagnosis due to its systemic involvement.
Constantine N. Logothetis, Joel Fernandez, Damian A. Laber   +2 more
doaj   +1 more source

Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial

Amyloid: Journal of Protein Folding Disorders, 2022
Background The study objective was to assess the effect of vutrisiran, an RNA interference therapeutic that reduces transthyretin (TTR) production, in patients with hereditary transthyretin (ATTRv) amyloidosis with polyneuropathy.
D. Adams, I. Tournev, Mark S. Taylor, T. Coelho, V. Planté-Bordeneuve, J. Berk, A. González-Duarte, J. Gillmore, S. Low, Y. Sekijima, L. Obici, Chongshu Chen, P. Badri, S. Arum, J. Vest, M. Polydefkis   +15 more
semanticscholar   +1 more source

Prevalence, characteristics and outcomes of older patients with hereditary versus wild‐type transthyretin amyloid cardiomyopathy

European Journal of Heart Failure, 2023
Transthyretin amyloid cardiomyopathy (ATTR‐CM) is often assumed to be associated with wild‐type TTR genotype (ATTRwt) in elderly patients (aged ≥70), some of whom are not offered genetic testing.
A. Porcari, Y. Razvi, A. Masi, R. Patel, A. Ioannou, M. Rauf, D. Hutt, D. Rowczenio, J. Gilbertson, A. Martinez-Naharro, L. Venneri, C. Whelan, H. Lachmann, A. Wechalekar, C. Quarta, M. Merlo, G. Sinagra, P. Hawkins, M. Fontana, J. D. Gillmore   +19 more
semanticscholar   +1 more source

Left Ventricular Structure and Function in Transthyretin-Related Versus Light-Chain Cardiac Amyloidosis

Circulation, 2014
Candida Cristina Quarta, Christian Gagliardi, Claudio Rapezzi   +2 more
exaly   +3 more sources